Edinburgh Worldwide beat its benchmark by a decent margin over the six months ended 30 April 2015, returning 14.7% on net assets vs. a 10.4% return for the benchmark, the S&P Citigroup Global Small Cap Index, the return to shareholders was even better at 17.7% as the discount narrowed from 8.5% to 6.1%. There is no interim dividend.
They say that a number of their holdings made positive contributions to performance but highlight the contributions from 4D Pharma, a UK based biotechnology company developing natural bacteria-derived therapeutics; Xeros Group, a UK developer a polymer bead based cleaning technology; and Galapagos, a Belgian biotechnology company.
EWI : Biotechs boost Edinburgh Worldwide